1629620-18-3

1629620-18-3 structure

Name: Suvratoxumab
Chemical Name: Suvratoxumab
CAS Number: 1629620-18-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2023-01-15 12:43:54
Modify Date: 2024-04-07 09:49:36
Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394)[1][2][3].

Name	Suvratoxumab

Description	Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394)[1][2][3].
Related Catalog	Research Areas >> Infection Research Areas >> Inflammation/Immunology Signaling Pathways >> Anti-infection >> Bacterial
Target	α-toxin of S. aureus[1][2][3].
In Vivo	Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) 可提高免疫功能低下的小鼠肺炎模型的存活率[1]。 Suvratoxumab (15 mg/kg; i.p.; single) 可减少小鼠的肺损伤并增加巨噬细胞的吞噬作用[1]。 Suvratoxumab (15 mg/kg; i.p.; single) 可增强抗生素（万古霉素或利奈唑胺）治疗小鼠的有效性[1]。 Animal Model: Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. Dosage: 5, 15, 45 mg/kg Administration: Intraperitoneal injection; single Result: Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU. Animal Model: Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. Dosage: 15 mg/kg Administration: Intraperitoneal injection; single Result: Prophylaxis protected the lungs of S. aureus-infected immunocompromised mice from α toxin-mediated damage.
References	[1]. Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. [2]. Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16. [3]. Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.

No Any Chemical & Physical Properties

2171856-85-0	2172555-59-6
2172216-41-8	2171977-91-4
2172549-12-9	2171856-93-0
2172152-33-7	2171966-87-1
2172549-36-7	2171978-07-5